Copernicus SOCT receives FDA clearance

Article

Reichert has received 510k clearance from the FDA to market the Reichert-Optopol Spectral Optical Coherence Tomographer (SOCT) in the US.

Reichert has received 510k clearance from the FDA to market the Reichert-Optopol Spectral Optical Coherence Tomographer (SOCT) in the US.

The Copernicus is designed for in vivo imaging and measurement of the retina by using spectral tomography to rapidly create high-resolution images of retinal structures. These detailed three-dimensional images enhance a physician's ability to diagnose and monitor retinal disease and perform pre- and post procedural assessments of patients.

The SOCT was the first commercially available device on the world market.

Related Videos
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Giulia Corradetti, MD, discusses her presentation "Functional Microperimetric Correlates of OCT Structures Features in Intermediate AMD"
At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network
Baruch Kuppermann, MD, PhD
At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns."
Ash Abbey, MD, shares 36-month data from the GALE study of pegcetacoplan
© 2024 MJH Life Sciences

All rights reserved.